Tech Session V: Gene Delivery and Gene Editing III
Advancing T cell therapy: mRNA nanocarriers optimization for ex vivo and in vivo T cell engineering
Thursday, July 17, 2025
11:16 AM - 11:27 AM EDT
Location: 119 A
Introduction: Despite T cell therapy clinical success, the increasing number of treated patients has highlighted significant limitations in the manufacturing process (1-2). High production costs and the bottleneck in viral vector supply to engineer patient T cells hinder the broad application of these life-saving therapies. As nanotechnology offers an alternative for T cells engineering, we aim to optimize mRNA-nanocarriers (NCs) for: (i) Ex vivo T cell engineering as a viral-free alternative. (ii) In vivo T cell engineering as a universal approach, removing the need for patient-specific therapies (3).
Learning Objectives:
At the completion of this activity, participants will know
Identify the challenges to produce mRNA-loaded NCs for high, stable transfection of primary T cells.
Explore mRNA-NCs potential for T cell engineering for development of improved T cell therapy.
Evaluate the potential of mRNA-NCs in transfecting primary T cells as alternative to viral vectors.
Alberto Jiménez – PhD student, University of Santiago de Compostela; Philipp Lapuhs – PhD student, University of Santiago de Compostela; Naiara Doldán – Undergraduate student, University of Santiago de Compostela; Mariona Baliu-Piqué – Technical Director, Advanced Therapies Manufacturing Center, Galaria Inc; Lucía Sanjurjo – Post Doctoral researcher, Health Research Institute of Santiago de Compostela (IDIS); María José Alonso – Full professor, University of Santiago de Compostela
